These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25119170)

  • 21. Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
    Osman WM; Youssef NS
    Int J Clin Exp Pathol; 2015; 8(7):8165-77. PubMed ID: 26339385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of tumour supressor protein p53 in renal cell carcinoma patients.
    Hodorova I; Solar P; Mihalik J; Vecanova J; Adamkov M; Rybarova S
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):44-9. PubMed ID: 23073516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
    Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
    Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
    Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
    J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
    Ito E; Saito K; Takizawa T; Koike M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interaction between p53 and MDM2 in human lung cancer cells].
    Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
    Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
    Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
    Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of Mdm2 and p53 in feline mammary gland tumors.
    Nakano M; Wu H; Taura Y; Inoue M
    J Vet Med Sci; 2006 May; 68(5):421-5. PubMed ID: 16757883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-metastatic clear cell renal carcinoma: prognostic significance of morphometric and biomolecular factors].
    Iurin AG
    Vopr Onkol; 2009; 55(2):177-82. PubMed ID: 19514371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
    Pinto AE; André S; Laranjeira C; Soares J
    Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.
    Abd-Elhamid ES; Elmalahy MH
    Diagn Pathol; 2010 Nov; 5():72. PubMed ID: 21092204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
    Kim Y; Choi JW; Lee JH; Kim YS
    Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical detection of p53 and MDM2 expressions in liposarcoma with World health organization classification.
    Arici A; Ozgur T; Ugras N; Yalcinkaya U
    Indian J Cancer; 2013; 50(3):164-9. PubMed ID: 24061453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
    Sabah M; Cummins R; Leader M; Kay E
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):64-9. PubMed ID: 17536310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
    Montgomery RM; Queiroz Lde S; Rogerio F
    Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
    Diolombi ML; Cheng L; Argani P; Epstein JI
    Am J Surg Pathol; 2015 Dec; 39(12):1621-34. PubMed ID: 26426379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.